MTCYBP19

Across TCGA pan-cancer cohorts, MTCYBP19 RNA is linked to patient survival in 17 of 34 cancer types, making it the most broadly survival-associated MTCYBP19 data layer.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher MTCYBP19 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MTCYBP19 expression acts as an unfavorable survival marker, although some lineages such as CESC and SKCM show a favorable association.

CHOL, STAD, and ACC are the cancer types where MTCYBP19 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	DFS	Tertile	II,III,IV	0.016	0.406	<.001	99	view →
STAD	DFS	Quartile	II,III,IV	0.528	0.724	.001	57	view →
ACC	DFS	Tertile	IV	0.012	0.310	.002	54	view →
CESC	DFS	Tertile	All	0.950	0.800	.008	54	view →
TGCT	OS	Tertile	II,III,IV	0.670	1.000	.005	36	view →
COAD	DFS	Tertile	II,III,IV	0.586	0.776	.004	27	view →
LIHC	OS	Tertile	II,III,IV	0.460	0.673	.009	26	view →
SKCM	OS	Tertile	All	0.938	0.856	.005	18	view →
LUAD	DFS	Tertile	IV	0.047	0.565	<.001	18	view →
LUSC	OS	Tertile	III,IV	0.386	0.794	.035	18	view →
THCA	DFS	Tertile	II,III,IV	1.000	0.480	.015	15	view →
LGG	OS	Tertile	All	0.686	0.482	.024	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 17 lineages.

MTCYBP19–CHOL (DFS)

Open the CHOL breakdown →